Leukemia Clinical Trials in Houston

Showing 1101-1120 of 1,435 trials

PKC412 and 5-Azacytidine

NCT01202877

The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.

Leukemia

M.D. Anderson Cancer Center54 participantsStarted Mar 2011

Houston, Texas, United States

TERMINATEDPhase 2< 1 mile

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

NCT02469415

The goal of this clinical research study is to learn if pacritinib, either alone or in combination with azacitidine or decitabine, can help to control MDS. The safety of this drug and drug combination will also be studied.

Leukemia

M.D. Anderson Cancer Center3 participantsStarted Sep 2015

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

NCT01025154

The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old. The safety of this study drug combination will also be studied.

Acute Myeloid Leukemia

M.D. Anderson Cancer Center63 participantsStarted Jan 2010

Houston, Texas, United States

PKC412 and 5-Azacytidine

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Leukemia Trials in Other Cities

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

An Open-label Phase II Study of Lorvotuzumab Mertansine

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Other Conditions in Houston